finance.yahoo.com ·
Puma Biotechnology Q1 Earnings Call
Topic context
This topic has been covered 384045 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPuma Biotechnology's Q1 earnings show a commercial mechanism of inventory destocking (channel: inventory_destock) that temporarily depressed unit sales despite rising new prescriptions. The raised guidance signals confidence in underlying demand. The alisertib pipeline is early-stage with no immediate revenue impact. Impact is single-company/supply-chain-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 total revenue $44.8M, NERLYNX product revenue $42.0M
- GAAP net loss $3.8M
- Full-year NERLYNX revenue guidance raised to $202–$206M
- NERLYNX unit sales fell to 2,328 bottles from 3,298 in Q4 2025 due to $7.9M inventory drawdown
- New prescriptions rose ~25%; interim Phase II data for alisertib in SCLC and ER+ breast cancer
NERLYNX (neratinib) unit sales down 29% QoQ due to inventory destocking; revenue pressure expected in the next 48h.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
